Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

NCT01517529 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2015-11-20

Study results available
· View outcomes & findings →

Summary

The major goal of this project is to identify the role of the immune responses in the emergence of protease inhibitor mutants during therapy.

Conditions

  • Hepatitis C

Sponsors & Collaborators

Principal Investigators

  • Mohamed Tarek. M Shata, MD, PhD · University of Cincinnati

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-07-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01517529 on ClinicalTrials.gov